Complement 3 Glomerulopathy (C3G) Market Size & Share, by Treatment Type (Anti-Complement Therapy, Cellular Immune Suppression, Plasma therapy); End-User (Hospitals, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5781
  • Published Date: Mar 01, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Complement 3 Glomerulopathy Market size is anticipated to cross USD 68 Million by the end of 2036, growing at a CAGR of 3% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of complement 3 glomerulopathy (C3G) was over USD 45 Million. The expansion of the market has been facilitated by the close connection between nephrology and the healthy operation of several digestive processes in humans. The human body's urine bladder is crucial to preserving the health of Given these facts, it is reasonable to conclude that the secret to a long and healthy life is nephrological health. From now on, medical professionals are working nonstop to implement appropriate treatment plans for complement 3 glomerulopathy (C3G), a rare kidney illness. Also, the growing number of nephrologists is escalating the market growth. For instance, Australia employed 479 nephrologists in 2016, of whom 28.4% were employed by the private sector.

The suppliers vying for market share in the worldwide complement 3 glomerulopathy (C3G) space are developing their medications in stages. These vendors have divided their research lines based on the two forms of complement 3 glomerulopathy (C3G) that are common in humans: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD). The global complement 3 glomerulopathy market has expanded due to the medical industry's push to offer treatment alternatives that are centered around diseases.


Complement 3 Glomerulopathy Market
Get more information on this report: Request Free Sample PDF

Complement 3 Glomerulopathy (C3G) Sector: Growth Drivers and Challenges

Growth Drivers

  • Increased Incidences of Kidney Disorders – The increasing prevalence of kidney disorders, including complement 3 glomerulopathy (C3G), is driving the growth of the complement 3 glomerulopathy market. As per a report, the prevalence of kidney illness is rising alarmingly. Over 1 in 7 persons in America or 15% of the population, are afflicted by it at this time. Individuals of color are more likely to develop renal failure. Also, growing advancements in understanding the underlying mechanisms of C3G and developing targeted therapies such as complement inhibitors to modulate the dysregulated complement system. Additionally, there’s a focus on personalized medicine approach to tailor treatments based 0on individual patient characteristics and disease severity, which can lead to better outcomes for those affected by C3G.
  • Growing Research and Development Activities in Kidney Diseases - The most recent findings of unique kidney illnesses have also given complement 3 glomerulopathy market new avenues for prospective growth. The ability of the kidney to fight infections is greatly diminished in the presence of complement 3 glomerulopathy (C3G). As a result, new medications are being employed to treat the sickness. Due to the inherited nature of complement 3 glomerulopathy (C3G), medical researchers have been obliged to expand the scope of their study. Furthermore, there are numerous external pathways via which the illness can be caught, creating new opportunities for growth in the global market.
  • Increased Awareness Regarding the Disease – The development of targeted therapeutics and C3G options is receiving more attention as awareness increases. This encourages funding for research and development, which results in the release of novel medications and therapeutic approaches. Furthermore, greater public knowledge frequently sparks patient and healthcare organizations' lobbying efforts, which in turn can boost funding for research, improve treatment accessibility, and enhance services for C3G patients. Thus, as global awareness grows, so does the complement 3 glomerulopathy market for C3G-related goods and services, reaching a wider range of patients and medical professionals outside of conventional healthcare centers.

Challenges

  • High Costs of Treatment – The expense of treating C3G can be high, especially when supportive therapy and immunosuppressive medications are used. For certain patients, particularly in areas with little healthcare resources or insurance coverage, this financial burden may prevent them from receiving the best care possible. As a result, these factors can prevent the market from expanding.
  • Limited Therapies Approved for the Treatment of C3G may Impede the Market Growth
  • Limited Awareness Regarding the Condition may Hinder complement 3 glomerulopathy market Growth.

Complement 3 Glomerulopathy (C3G) Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~ 3%

Base Year Market Size (2023)

 ~ USD 45 Million

Forecast Year Market Size (2036)

 ~ USD 68 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Complement 3 Glomerulopathy (C3G) Segmentation

Treatment Type (Anti-Complement Therapy, Cellular Immune Suppression, Plasma therapy)

Anti-complement therapy segment for the complement 3 glomerulopathy (C3G) market is expected to hold a share of 47% during the forecast period. The treatment is gaining traction because it can effectively address a variety of disorders, including C3G, that involve dysregulated complement activation. The complement system is involved in many autoimmune diseases, inflammatory ailments, and immune system abnormalities, which makes this strategy more and more crucial. Anti-complement therapy tries to moderate excessive complement activation and associated tissue damage by blocking particular components, including C3 or C5. Anti-complement therapy is anticipated to grow as a viable treatment option for a range of complement-mediated illnesses as research into complement's role in disease pathogenesis continues, as well as the development of new medicines. For instance, by developing a new class of complementary medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, Annexon, Inc. is a clinical-stage biopharmaceutical company. The company announced encouraging final data from its open-label Phase 2 clinical trial of ANX005 in patients with Huntington's disease (HD).

End-User (Hospitals, Specialty Clinics)                                            

Hospitals segment in the complement 3 glomerulopathy market is anticipated to hold the largest share of 55% during the forecast period. An increasing number of C3G instances are being found as a result of increased awareness and better diagnostic methods. As a result, there will be a greater need for medical services such as continuing disease management, consultations, and diagnostic testing. Additionally, in order to manage symptoms and problems, persons with C3G need to have their status regularly monitored. Support services may also be necessary. In addition, clinical trials and research studies are frequently carried out by healthcare facilities in an effort to improve knowledge and treatment choices for C3G. As a result, these elements are supporting the segment's expansion.

Our in-depth analysis of the global complement 3 glomerulopathy (C3G) market includes the following segments:

          Treatment Type

  • Anti-Complement Therapy
  • Cellular Immune Suppression
  • Plasma therapy

          End-user

  • Hospitals
  • Specialty Clinics

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Complement 3 Glomerulopathy Industry - Regional Synopsis

North American Market Forecast

North American complement 3 glomerulopathy market is expected to hold a share of 36% during the forecast period. The increase can be attributed to the region's increasing incidence of kidney disorders. Additionally, the region's growing hospital and specialty clinic population is fueling market expansion.

European Market Statistics

Complement 3 glomerulopathy market in Europe is poised to grow with a share of 28% by the end of 2036. Europe has come a long way in creating and implementing sophisticated kidney disease diagnostic methods, such as C3G. Additionally, the number of clinical studies for the illness being conducted in the area is driving the market's expansion. The regulatory landscape in Europe is favorable to the creation and monetization of orphan medications and the management of uncommon illnesses such as C3G.

Research Nester
Complement 3 Glomerulopathy Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Complement 3 Glomerulopathy Landscape

top-features-companies
    • Novartis AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Apellies Pharmaceutical
    • Amyndas Pharmaceuticals SA
    • Kira Pharmaceuticals
    • Alexion Pharmaceuticals Inc.
    • Omeros Corporation
    • Amgen Inc.
    • Sobi®
    • Boehringer Ingelheim International GmbH.
    • AstraZeneca

In-the-news

In The News

  • Positive topline findings from the six-month, double-blind Phase III APPEAR-C3G study of iptacopan for the treatment of patients with C3 glomerulopathy (C3G)1 were released by Novartis today. The primary goal of the research was achieved, as iptacopan (200 mg twice daily) showed superiority over placebo in reducing proteinuria (protein in urine) on top of background medication in a way that was both clinically relevant and statistically significant at six months1. Iptacopan's safety profile matched data1-3 that had previously been published.
  • Positive findings from the Phase 2 NOBLE study examining pegcetacoplan for the treatment of post-transplant recurrence of primary immune complex membranproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) will be presented at the Kidney Week Annual Meeting of the American Society of Nephrology (ASN), from Sobi® and Apellis Pharmaceuticals, Inc.

Author Credits:  Smruti Ranjan, Rajrani Baghel


  • Report ID: 5781
  • Published Date: Mar 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increased Incidences of Kidney Disorders, Growing Research and Development Activities in Kidney Diseases, and Increased Awareness Regarding the Disease are the major factors driving the growth of the Complement 3 Glomerulopathy (C3G) market.

The market size of Complement 3 Glomerulopathy (C3G) is anticipated to attain a CAGR of 3% over the forecast period, i.e., 2024-2036.

The major players in the market are Novartis AG, Apellies Pharmaceutical, Amyndas Pharmaceuticals SA, Kira Pharmaceuticals, Alexion Pharmaceuticals Inc., Omeros Corporation, Amgen Inc., Sobi, Boehringer Ingelheim International GmbH., AstraZeneca, and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Complement 3 Glomerulopathy Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying